|
 |
RemodulinThis page contains recent news articles, when available, and an overview of Remodulin but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.The pulmonary arterial hypertension drug treprostinil (Remodulin) may be more effective than it's given ... MedPage Today United Therapeutics Shares Rise On Bullish Tyvaso Comments - Dec 16, 2009 Tyvaso is an inhaled version of Remodulin, which costs $125000 a year and is administered either as a continuous intravenous infusion or under-the-skin ... Wall Street Journal Wedbush Maintains a 'Neutral' on United Therapeutics (UTHR); Raises PT & Estimates - Dec 17, 2009 ...major change in valuation until late 2010 or early 2011, when we may see initial data release of Phase 3 data from the oral Remodulin clinical program. ... StreetInsider.com (subscription) Going its own way - Nov 12, 2009 Rothblatt purchased the compound that's now sold as Remodulin from GlaxoSmithKline for just $25000 in 1997, and made initial investments to get United off ... Business Gazette United Therapeutics Corporation Reports Third Quarter 2009 Financial Results - Oct 29, 2009 ..."Equally important, our flagship product, Remodulin, achieved its highest quarterly sales levels ever. Taken together, these therapies evidence our keen ... Reuters Takeover likely for United, analyst says - Nov 12, 2009 Also, the company's focus "is entirely on Remodulin," and "there is not a deep pipeline behind that, meaning that an acquirer could have no trouble ... Business Gazette Study Finds Life-Threatening Risks from Medication Errors in Hospitals ... - Nov 4, 2009 ...medication errors for patients infused with epoprostenol (Flolan®) and treprostinil (Remodulin®) and provided guidelines to help reduce these risks. ... Reuters United Therapeutics Trips Over Remodulin - Nov 17, 2008 United Therapeutics has what seems like an embarrassing problem: an oral form of its blood-pressure drug turns out not to have worked as expected, and, ... Forbes United Therapeutics Shares Soar on FDA Report - Nov 2, 2007 United Therapeutics's lead product is Remodulin, which treats the rare ... With the new form of Remodulin, called Viveta, patients would inhale the drug ... Washington Post Study Raises Questions For United Therapeutics - Feb 27, 2007 United Therapeutics said Monday it will work closely with the pulmonary group to improve patient care using Remodulin, and that it planned to begin a ... Washington Post United Therapeutics Profit Nearly Triples, to $12.2 Million | Article... - Aug 3, 2005 Also, Remodulin stays in the body for more than four hours, compared with Flolan's ... And Remodulin, while expensive at about $100000 a year per patient, ... Pay-Per-View - Washington Post - HighBeam Research United Therapeutics shares plunge on failed study - Nov 17, 2008 Remodulin is already sold as an injectable treatment, and the Food and Drug ... Doses of Remodulin were given in combination with one of two other current ... Boston Globe Business is personal for satellite radio, drug entrepreneur - Apr 26, 2008 Rothblatt's company, Silver Spring, Md.-based United Therapeutics, obtained FDA approval for the drug, Remodulin, and is developing new, improved treatments ... FOXNews Biotech's shares decline 12 percent: Management change, drop in... - Aug 2, 2006 They include customer stockpiling of its lead drug Remodulin, which treats a blood vessel disorder in the lungs, as well as a rise in the number of ... Free with registration - Baltimore Sun - AccessMyLibrary.com … and Mochida Pharmaceutical Sign Remodulin Distribution Agreement... - Mar 27, 2007 ..."Remodulin is expected to provide many advantages over currently approved ... Remodulin(R) is approved in the United States as a continuous subcutaneous ... Free with registration - PR Newswire - AccessMyLibrary.com FDA Approves United Therapeutics' Remodulin Label Expansion - Mar 23, 2006 The FDA has approved United Therapeutics' supplemental new drug application for its pulmonary arterial hypertension drug Remodulin injection, granting the ... RedOrbit United Therapeutics Announces Approval of Remodulin(R) in France. - Mar 8, 2005 SILVER SPRING, Maryland and RESEARCH TRIANGLE PARK, North Carolina, March 8 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today ... Free with registration - PR Newswire Europe - AccessMyLibrary.com United Therapeutics applies for OK for new version of Remodulin - Jun 30, 2008 United Therapeutics Corp. has requested federal approval to start selling an inhaled version of its pulmonary arterial hypertension drug on the market. ... Bizjournals.com United Therapeutics (UTHR) Receives NDA from FDA for Remodulin - Mar 21, 2006 United Therapeutics (Nasdaq: UTHR) announced that the United States Food and Drug Administration (FDA) has approved a supplemental New Drug Application ... StreetInsider.com - StreetInsider.com (subscription) MedImmune Inc. One MedImmune ... - May 1, 2006 While Remodulin must constantly be pumped into the body, it doesn't have to be frozen and ... Also, Remodulin stays in the body for more than four hours, ... Pay-Per-View - Washington Post - ProQuest Archiver Competition looms for Silver Spring drugmaker - Dec 14, 2005 Following a full year of expanded sales of its lead product, Remodulin, ... Remodulin treats pulmonary arterial hypertension, a life-threatening disease ... Business Gazette United Therapeutics Q3 profit trails Street view - Oct 30, 2008 Revenue rose to $75 million, helped by growth in sales of its lead drug Remodulin for pulmonary arterial hypertension. ... Reuters United Therapeutics gets patent extension - Feb 23, 2005 Remodulin is used to treat pulmonary hypertension, a rare form of high blood pressure in the lungs. Only a few hundred patients worldwide take the drug, ... Bizjournals.com Event Brief of Q4 2006 United Therapeutics Earnings Conference Call -... - Feb 20, 2007 UTHR has 70 patients enrolled in the FREEDOM trial of oral Remodulin, 52 patients in the ... In the very innovative oral Remodulin monotherapy trial, ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com United Therapeutics shares rise after co. swings to profit - May 1, 2008 Revenue jumped 54 percent to $62 million from $40.2 million a year earlier, driven by strong sales of its lead product, Remodulin. The injection is used to ... Boston Globe Event Brief of Q3 2006 United Therapeutics Earnings Conference Call -... - Oct 31, 2006 So many patients remain quite happy on subcutaneous Remodulin, and for the patients who then want to go on to intravenous Remodulin because of the site pain ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Inhaled Form of Remodulin in the Pipeline - Oct 28, 2005 ...by John C. Martin. People prescribed Remodulin may soon have another way to take the medication. Pharmaceutical manufacturer United Therapeutics, ... PH Neighborhood Options Update: United Therapeutics Puts Popular on Failed Remodulin ... - Nov 17, 2008 The brokerage firm reiterated its "sell" rating on UTHR and noted that it has low expectations for success on another late-stage Remodulin study. ... Schaeffers Research Improved Long-Term Outcome With Remodulin Reported in European … - Feb 1, 2007 SILVER SPRING, Md., Feb. 1 /PRNewswire-FirstCall/ -- United Therapeutics Corporation announced the publication of two important studies: ... $4.95 - PR Newswire - ECNext United Thera: EU MRP ends for Remodulin.(United Therapeutics Corp.)( … - Aug 22, 2005 United Therapeutics Corp of the USA says that, following the first European Union approval in France earlier this year (Marketletter March 14), ... $4.95 - Pharma Marketletter - ECNext … Ministry of Health Approves Intravenous Dosing of Remodulin(R) to... - Jan 10, 2006 The Israeli approval represents the third national approval of intravenous Remodulin following United States Food and Drug Administration approval on ... RedOrbit … : Improved Long-Term Outcome With Remodulin Reported in European … - Feb 1, 2007 Improved Long-Term Outcome With Remodulin Reported in European Respiratory Journal and Rapid Transition to Remodulin Reported in Journal of Cardiovascular ... Pay-Per-View - PR Newswire - HighBeam Research … Announces Positive Results from Trust Study of Intravenous Remoduli... - Dec 19, 2005 Specifically, intravenous Remodulin produced an 83-meter median improvement ... Intravenous Remodulin is currently approved in the United States and Canada ... biotech-intelligence.com United Therapeutics' net drops 96% on higher costs - Feb 19, 2008 United Therapeutics credited growth in sales of pulmonary hypertension drug Remodulin, its best-selling treatment. In the fourth quarter, ... Bizjournals.com NO CURE FOR HUNTINGTON'S - Jan 28, 2007 Tracleer (bosentan) and Remodulin (treprostinil) are two of the newer drugs. Revatio is the newest. It is Viagra, the same medicine used to overcome male ... Pay-Per-View - South Florida Sun - Sentinel - ProQuest Archiver Revenue up, but below target at Silver Spring-based United Therapeutic... - Feb 22, 2006 She said the $28.5 million in Remodulin sales in the fourth quarter was short of her ... She noted several positive signs for Remodulin, including new sales ... Free with registration - Daily Record - AccessMyLibrary.com … Therapeutics Completes European Mutual Recognition for Remodulin(R)... - Aug 10, 2005 ..."Our pursuit of the European approvals and resubmissions demonstrates our commitment to making Remodulin available as widely as practical," ... $4.95 - PR Newswire - ECNext United Therapeutics Guidance Announcement - Part 2. - Feb 26, 2007 And she does have a number of friends who are on Flolan, Remodulin and what have you. And she pointed out that looking at things as a patient the ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Maryland-based biotech firm plans Durham County, NC, plant. - May 10, 2006 The plant will produce a tablet form of the firm's Remodulin therapy, which is a hypertension treatment. The drug, sold as an injectable, is the company's ... Free with registration - Herald Sun - AccessMyLibrary.com … European Mutual Recognition for Remodulin(R). - PR Newswire | High - Aug 10, 2005 Remodulin to be Approved in 22 Additional European Union Countries with ... (Remodulin currently is reimbursed in a number of European countries on a ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: United Therapeutics Announces FDA Approval of … - Mar 21, 2006 In the trial, 13 of 14 patients (93%) randomized to Remodulin were able to ... "This study confirms the clinical benefit of Remodulin in pulmonary arterial ... Pay-Per-View - PR Newswire - HighBeam Research Q4 2004 United Therapeutics Earnings Conference Call - Final. - Feb 22, 2005 Can you provide an update on the Inhale Remodulin program and what we can expect to see in the first half of '05? And if we are expecting a randomized trial ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com United Thera and Mochida sign Remodulin deal for Japan. - Apr 2, 2007 United Thera and Mochida sign Remodulin deal for Japan. US firm United Therapeutics and Japan's Mochida Pharmaceutical have signed an agreement for the ... $9.94 - Pharma Marketletter - Alacra Store United Therapeutics' Profit Surges; But 4th-Quarter Figures Fall... - Feb 22, 2006 During a conference call with analysts and investors, company executives blamed the results on seasonal choppiness in sales for its lead product, Remodulin. ... Pay-Per-View - Washington Post - HighBeam Research FDA Warns United Therapeutics Over Remodulin Promotions - Apr 27, 2005 A journal advertisement and booklet for United Therapeutics hypertension drug Remodulin minimize risk information and make unsubstantiated effectiveness ... Pay-Per-View - FDAnews Drug Daily Bulletin - Factiva, from Dow Jones … and Mochida Pharmaceutical Sign Remodulin Distribution Agreement... - Mar 27, 2007 United Therapeutics and Mochida Pharmaceutical Sign Remodulin Distribution Agreement for Japan. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research International Approvals: Tasmar, Amplimexon, IV Remodulin - Jan 17, 2006 Jan. 17, 2006 — Tolcapone tablets have been reintroduced in the UK market after a 7-year suspension by the European Medicines Evaluation Agency; ... Medscape Markets Media Online - Driven by Content - Sep 9, 2008 United Therapeutics is best known for its hypertension drug Remodulin. The Food and Drug Administration is currently reviewing a new inhaled hypertension ... Markets Media News United Therapuetics Draws Warning Letter for Remodulin Promotions - Apr 19, 2005 A journal advertisement and booklet for United Therapeutics hypertension drug Remodulin minimize risk information and make unsubstantiated effectiveness ... Pay-Per-View - Drug Industry Daily - Factiva, from Dow Jones Article: Remodulin linked to high rate of bloodstream infections - Mar 1, 2007 Remodulin, a lung disorder drug manufactured by Silver Spring- based United Therapeutics Corp., has been linked to a higher rate of bloodstream infections ... Pay-Per-View - Daily Record - HighBeam Research … ; US FDA approves IV dosing of Remodulin for pulmonary arterial … - Jan 2, 2005 ...(UTHR) announced that the US Food and Drug Administration (FDA) has issued an approval letter for the intravenous (IV) use of Remodulin based on data ... Pay-Per-View - Medical Letter on the CDC & FDA - Factiva, from Dow Jones United Therapeutics' Profit Surges - Feb 22, 2006 During a conference call with analysts and investors, company executives blamed the results on seasonal choppiness in sales for its lead product, Remodulin. ... Washington Post FDA: Remodulin ads misleading.(Digest)(Food and Drug Administration)(... - May 2, 2005 The Food and Drug Administration has ordered United Therapeutics Corp. to withdraw an advertisement for Remodulin. The regulatory agency asserts that the ... Free with registration - Chain Drug Review - AccessMyLibrary.com United Therapeutics shares rise on 4Q gains - Feb 20, 2007 Fourth quarter revenue also swelled in 2006, nearly topping $46 million on strong sales of Remodulin, a drug used to treat pulmonary arterial hypertension. ... Triangle Business Journal Event Brief of Q3 2006 United Therapeutics Earnings Conference Call -... - Oct 3, 2006 So many patients remain quite happy on subcutaneous Remodulin, and for the patients who then want to go on to intravenous Remodulin because of the site pain ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com International Approvals: Ceplene, Reducol, Remodulin - Mar 14, 2005 March 14, 2005 — The European Commission has approved orphan drug status for histamine dihydrochloride, allowing its use in the European Union for the ... Medscape Chuck Jaffe: United Therapeutics is priced for success it may not... - Sep 4, 2008 The company's primary drug is Remodulin, which is used to treat pulmonary ... Second-quarter sales of Remodulin were up 33%, and with limited competition, ... MarketWatch United Therapeutics reports 70 percent jump in revenue - May 3, 2005 The gain in sales came primarily from increased sales of Remodulin, ... It also recently won an five-year extension on its patent for Remodulin, ... Washington Business Journal … : United Therapeutics Announces Approval of Remodulin(R) in France.... - Mar 8, 2005 United Therapeutics Announces Approval of Remodulin(R) in France. ... find PR Newswire Europe articles. SILVER SPRING, Maryland and RESEARCH TRIANGLE PARK, ... Pay-Per-View - PR Newswire Europe - HighBeam Research United Therapeutics foresees solid growth - Dec 9, 2005 Following a full year of expanded sales of its lead product, Remodulin, ... Remodulin treats pulmonary arterial hypertension, a life-threatening disease ... Business Gazette United Therapeutics Reports First Quarter 2006 Financial Results. - May 2, 2006 The increases in revenues and gross margins resulted primarily from growth in sales of Remodulin. Net income was $2.3 million or $0.10 per basic share in ... $4.95 - PR Newswire - ECNext Article: FDA: Remodulin ads misleading.(Digest)(Food and Drug … - May 2, 2005 FDA: Remodulin ads misleading.(Digest)(Food and Drug Administration)(Brief Article) ... find Chain Drug Review articles. The Food and Drug Administration ... Pay-Per-View - Chain Drug Review - HighBeam Research United Therapeutics Profit Nearly Triples, to $12.2 Million - Aug 3, 2005 Also, Remodulin stays in the body for more than four hours, compared with Flolan's ... And Remodulin, while expensive at about $100000 a year per patient, ... Washington Post Strong drug sales boost United Therapeutics' third-quarter profits - Nov 1, 2005 United attributed much of that growth to increased sales of Remodulin, ... Rothblatt said the company expects to further increase Remodulin revenue by ... $2.95 - Daily Record - NewsBank Remodulin gets French OK.(Brief Article) - Mar 14, 2005 Remodulin (sodium treprostinil), an injectable treatment for New York Heart Association Class III Primary Pulmonary Hypertension from US firm United ... $4.95 - Pharma Marketletter - ECNext Article: Remodulin indicated as infusion.(PRODUCTS)(Brief Article) - ... - Feb 1, 2005 Remodulin indicated as infusion.(PRODUCTS)(Brief Article) ... find Internal Medicine News articles. Remodulin (treprostinil sodium) injection is indicated ... Pay-Per-View - Internal Medicine News - HighBeam Research Article: Remodulin indicated as infusion.(Products)(Brief Article) -... - Jun 1, 2005 Remodulin indicated as infusion.(Products)(Brief Article) ... find Family Practice News articles. Remodulin (treprostinil sodium) injection is indicated as ... Pay-Per-View - Family Practice News - HighBeam Research … five-year patent term extension for Remodulin. | Article from... - Feb 1, 2005 United Therapeutics granted five-year patent term extension for Remodulin. ... find BIOTECH Patent News articles. United Therapeutics Corporation (Silver ... Pay-Per-View - BIOTECH Patent News - HighBeam Research … Therapeutics granted five-year patent term extension for Remodulin. - Feb 1, 2005 ...term extension by the United States Patent and Trademark Office for its patent covering the method of treating pulmonary hypertension using Remodulin. ... $4.95 - BIOTECH Patent News - ECNext United Therapeutics moves on to ovarian cancer drug, new labs - Apr 28, 2006 United Therapeutics' fortunes have been fueled by sales of Remodulin, ... The company licensed Remodulin from pharmaceutical giant GlaxoSmithKline, ... Business Gazette TECHNOLOGY Sinclair Extends D ... - Mar 2, 2007 United Therapeutics' lung-disorder drug, Remodulin, was linked to a higher rate of ... Remodulin is injected and comes in vials containing several doses, ... Pay-Per-View - Washington Post - ProQuest Archiver … Announces Positive Results from Trust Study of Intravenous Remoduli... - Dec 19, 2005 Specifically, intravenous Remodulin produced an 83-meter median improvement ... Intravenous Remodulin is currently approved in the United States and Canada ... Pay-Per-View - PR Newswire - HighBeam Research United Therapeutics profits jump 147% - Jul 31, 2008 United Therapeutics credited growth in sales of Remodulin, its best-selling drug that treats pulmonary hypertension, for lifting revenue to $68.6 million ... Bizjournals.com United Therapeutics (UTHR) - Sep 14, 2008 The company's primary drug is Remodulin, which is used to treat pulmonary ... Second-quarter sales of Remodulin were up 33 percent, and with limited ... Seattle Times Medtronic Announces Expanded Labeling for Its Model 407C General … - Apr 19, 2005 The new labeling allows Remodulin to be administered to patients ... Remodulin is an FDA approved drug as a continuous subcutaneous infusion or intravenous ... RedOrbit Q2 2005 United Therapeutics Earnings Conference Call - Final. - Aug 2, 2005 I'd point out that this is our first full quarter of IV Remodulin revenues after launching IV Remodulin during a first quarter 2005. ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Frontline Tech Corp Ltd acquires Accel Frontline Ltd from Accel Ltd -... - Feb 14, 2006 FDA approved Remodulin under its accele rated approval regulations based on…#### -- Abgenix, Inc. and Dyax Corp . announced that they have entered… ... Pay-Per-View - deals - Alacra Store United Therapeutics Reports Second Quarter 2005 Financial Results and... - Aug 2, 2005 ..."Use of Remodulin(R) is increasing as awareness and appreciation of its ... Specifically, 13 of 14 patients (93%) in the Remodulin arm were able to ... $4.95 - PR Newswire - ECNext An entrepreneur starts a biotech to save her daughter's life - Jun.... - Jun 25, 2007 In 2002 the FDA approved the company's first version of Remodulin, ... Remodulin, which patients inject under their skin, lasts as long as three hours in a ... CNNMoney.com Merger and Acquisition Scenario - Mar 22, 2006 Buyer (Total: 22). UT-15C; Beraprost SR; Remodulin (Treprostinil Sodium); Inhaled Remodulin (Treprostinil). Target (Total: 11) ... $250.00 - Revere Reports - Revere Monopol wrocÅ‚awskiej apteki na drogi lek - Aug 21, 2007 Remodulin jako lek niezarejestrowany w Polsce byÅ‚ sprowadzany wyÅ‚Ä…cznie jako ... Remodulin dystrybuuje austriacka firma. Mimo wielokrotnych prób nie udaÅ‚o ... Gazeta.pl United Therapeutics Leads the Charge - Sep 16, 2005 But Remodulin has found its niche as a second-line therapy for patients who ... Currently, Remodulin accounts for around 95% of United Therapeutics' sales ... TheStreet.com - TheStreet.com (subscription) Merger and Acquisition Scenario - Jul 29, 2006 Target (Total: 22). Inhaled Remodulin (Treprostinil); UT-15C; Remodulin (Treprostinil Sodium); Beraprost SR. Buyer. n/a. Target ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Jul 29, 2006 Target (Total: 22). Inhaled Remodulin (Treprostinil); UT-15C; Remodulin (Treprostinil Sodium); Beraprost SR. Buyer. Protherics Enfer TSE Diagnostic Kit ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Apr 22, 2006 Target (Total: 22). UT-15C; Beraprost SR; Remodulin (Treprostinil Sodium); Inhaled Remodulin (Treprostinil). Buyer. n/a. Target ... $250.00 - Revere Reports - Revere Prokuratura zajmie siÄ™ drogim lekiem - Aug 23, 2007 W ubiegÅ‚ym roku wrocÅ‚awski aptekarz tylko za Remodulin dostaÅ‚ z NFZ zwrot 3 razy wiÄ™kszy niż za pozostaÅ‚e refundowane leki. Interia MD-Based United Therapeutics Gets Extension on Biggest Drug - Feb 24, 2005 Remodulin delivers a synthetic version of a naturally occurring hormone called ... Remodulin is the only in its category to be delivered intravenously, ... RedOrbit JP Morgan adds United Therapeutics to US focus list - Sep 11, 2008 The market opportunity for oral Remodulin could top $700 million at peak, Meacham said, and added potential sales of oral Remodulin to the earnings model, ... Reuters Biotech eyes RTP location - Feb 17, 2006 The tablet form of Remodulin has yet to be approved by the FDA. ... Remodulin was developed by two former Glaxo Wellcome researchers, James Crow and Shelmer ... Triangle Business Journal United Therapeutics gibt Zulassung von Remodulin(R) in Frankreich … - Mar 8, 2005 Silver Spring, Maryland und Research Triangle Park, North Carolina (ots/PRNewswire) - United Therapeutics Corporation (Nasdaq: UTHR) hat heute bekannt ... presseportal.de Article: MedImmune Inc. One MedImmune ... - The Washington Post | … - Apr 25, 2005 United Therapeutics recorded a $15.4 million profit on $73.6 million in revenue, primarily on sales of Remodulin, a treatment for pulmonary arterial ... Pay-Per-View - Washington Post - HighBeam Research æŒ?田製薬ã€?肺動脈性肺高血圧症治療薬「Remodulin(R)ã€?ã?®è²©å£²æ¨©ã‚’å?–å¾— - Jan 22, 2007 Tokyo, Mar 28, 2007 - (JCN Newswire) - æŒ?ç”°è£½è–¬æ ªå¼?会社（TSE:4534ã€?本社：æ?±äº¬éƒ½ 新宿区ã€?社長：æŒ?ç”° 直幸）ã?¯ã€?ã?“ã?®ã?Ÿã?³ãƒ¦ãƒŠã‚¤ãƒ†ãƒƒãƒ‰ãƒ»ã‚»ãƒ©ãƒ”ューティクス社（ ... japancorp.net Merger and Acquisition Scenario - Jul 29, 2006 Target (Total: 22). Inhaled Remodulin (Treprostinil); UT-15C; Remodulin (Treprostinil Sodium); Beraprost SR. Buyer. Anda, Inc. Value In Pharmaceuticals ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Apr 1, 2006 Target (Total: 22). UT-15C; Beraprost SR; Remodulin (Treprostinil Sodium); Inhaled Remodulin (Treprostinil). Buyer. vCJD Immunoassay Kit; HTLV-III ELISA ... $250.00 - Revere Reports - Revere United Therapeutics Corp., Silver Spring, MD, April 13 (DDMAC).(HUMAN... - May 1, 2005 Remodulin is indicated for the treatment of pulmonary arterial hypertension in ... Further, the booklet compared Remodulin to Flolan, another drug indicated ... $4.95 - Warning Letter Bulletin - ECNext Merger and Acquisition Scenario - Jul 29, 2006 Target (Total: 22). Inhaled Remodulin (Treprostinil); UT-15C; Remodulin (Treprostinil Sodium); Beraprost SR. Buyer. ALTANA Chemie AG. Target ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Jul 29, 2006 Target (Total: 22). Inhaled Remodulin (Treprostinil); UT-15C; Remodulin (Treprostinil Sodium); Beraprost SR. Buyer. Breath-Actuated Inhaler (BAI) ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Jul 29, 2006 Target (Total: 22). Inhaled Remodulin (Treprostinil); UT-15C; Remodulin (Treprostinil Sodium); Beraprost SR. Buyer. Gadofluorine Derivative; Berlex Vasovist ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Jul 29, 2006 Target (Total: 22). Inhaled Remodulin (Treprostinil); UT-15C; Remodulin (Treprostinil Sodium); Beraprost SR. Buyer. Ortho Diagnostics Valumetrix Services ... $250.00 - Revere Reports - Revere AMP Private Equity Fund III acquires a minority stake in Orphan... - Mar 9, 2005 Trial Details July ##, #### Orphan Australia Pty Ltd announc ed that Remodulin… ORPHAN AUSTRALIA PTY LTD.-COMPANY INSIGHT · ORPHAN AUSTRALIA PTY LTD. ... Pay-Per-View - deals - Alacra Store Merger and Acquisition Scenario - Apr 1, 2006 Buyer (Total: 22). UT-15C; Beraprost SR; Remodulin (Treprostinil Sodium); Inhaled Remodulin (Treprostinil). Target (Total: 71) ... $250.00 - Revere Reports - Revere MedImmune Inc. One MedImmune ... - Apr 25, 2005 United Therapeutics recorded a $15.4 million profit on $73.6 million in revenue, primarily on sales of Remodulin, a treatment for pulmonary arterial ... Pay-Per-View - Washington Post - ProQuest Archiver Rocket-Launch-Venture Approval Delayed - Dec 19, 2005 United Therapeutics of Silver Spring said that in a study, its Remodulin treatment ... Patients given Remodulin were able to walk an average of 83 meters ... Washington Post United Therapeutics Leads the Charge - Sep 21, 2005 Enter United Therapeutics and its PAH-fighter, Remodulin. Remodulin is a so-called prostacyclin analog, like Flolan, but it's much more convenient and less ... TheStreet.com - TheStreet.com (subscription) United Therapeutics Unites R and D - Aug 2, 2007 Shares of United have been on a tear, up 40% in the past six months as sales of its lead drug, pulmonary arterial hypertension (PAH) treatment Remodulin, ... fool.com PAH: Market ripe for expansion as big pharma interest increases. - Mar 21, 2006 ..."While physicians largely prefer Remodulin for its convenience, ... As such, Datamonitor expects Remodulin to become the worldwide prostacyclin class leader ... Free with registration - M2 Presswire - AccessMyLibrary.com Merger and Acquisition Scenario - Sep 6, 2008 Its principal prostacyclin analog is Remodulin, a treprostinil-based compound ... Remodulin (treprostinil sodium) Injection, has been approved by the United ... $250.00 - Revere Reports - Revere |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |